Valuation: SD Biosensor, Inc.

Capitalization 1,050B 719M 609M 560M 530M 983M 66.52B 1B 6.56B 2.57B 32.25B 2.7B 2.64B 114B P/E ratio 2024
-12.8x
P/E ratio 2025 -2.08x
Enterprise value 949B 650M 550M 506M 479M 888M 60.12B 904M 5.93B 2.33B 29.14B 2.44B 2.39B 103B EV / Sales 2024
2.02x
EV / Sales 2025 1.36x
Free-Float
28.55%
Yield 2024
1.95%
Yield 2025 -
1 day-5.69%
1 week+7.07%
Current month+14.77%
1 month+9.75%
3 months+6.81%
6 months-8.35%
Current year-1.35%
1 week 8,150
Extreme 8150
9,560
1 month 7,390
Extreme 7390
9,560
Current year 7,100
Extreme 7100
9,560
1 year 7,100
Extreme 7100
13,550
3 years 7,100
Extreme 7100
23,050
5 years 7,100
Extreme 7100
81,000
10 years 7,100
Extreme 7100
81,000
Manager TitleAgeSince
Chief Executive Officer 62 -
Sales & Marketing 39 -
Compliance Officer 47 -
Director TitleAgeSince
Director/Board Member 55 -
Director/Board Member 62 -
Director/Board Member 64 -
Change 5d. change 1-year change 3-years change Capi.($)
-5.69%+7.07%-2.12%-58.49% 762M
-1.42%-0.06%-20.40%-7.19% 12.71B
+0.89%+10.93%+114.02%+270.71% 11.85B
+0.47%+10.51% - - 5.98B
-0.32%+2.23%-17.02%-6.83% 5.45B
-0.26%-2.31%-11.52%-21.49% 5.24B
+6.54%-13.44%+117.56%+74.98% 4.64B
-0.70%+2.58%-35.80%-35.32% 3.96B
-2.40%+6.59%+227.28%-52.73% 3.33B
-0.32%-1.42%-14.90%-42.30% 2.86B
Average -0.32%+5.91%+39.68%+13.48% 5.68B
Weighted average by Cap. +0.12%+6.61%+40.47%+55.79%

Financials

2024 2025
Net sales 695B 475M 403M 371M 351M 650M 43.99B 661M 4.34B 1.7B 21.33B 1.78B 1.75B 75.16B 711B 486M 412M 379M 359M 665M 45.01B 677M 4.44B 1.74B 21.82B 1.82B 1.79B 76.9B
Net income -98.41B -67.36M -57.06M -52.5M -49.69M -92.09M -6.23B -93.71M -615M -241M -3.02B -253M -247M -10.65B -512B -351M -297M -273M -259M -479M -32.44B -488M -3.2B -1.25B -15.72B -1.31B -1.29B -55.42B
Net Debt 143B 97.96M 82.98M 76.35M 72.26M 134M 9.06B 136M 894M 351M 4.39B 367M 360M 15.49B -101B -69.23M -58.64M -53.96M -51.07M -94.64M -6.41B -96.31M -632M -248M -3.11B -260M -254M -10.94B
Logo SD Biosensor, Inc.
SD Biosensor Inc is a Korea-based company mainly engaged in the development and sale of in vitro diagnostics. The Company is engaged in the immunochemical diagnosis, molecular diagnosis, point-of-care diagnosis (POCTs), and self blood glucose measurement business. The Company is engaged in the research, development and sale of products such as rapid immunochemical diagnosis products, immunochemical fluorescence diagnosis products, molecular diagnosis products, enzyme immunological reaction diagnosis products and others. The Company distributes its products within domestic market and to overseas markets.
Employees
576
Date Price Change Volume
19/04/26 8,780.00 -5.69% 290,013
17/04/26 9,310.00 +6.77% 952,793
16/04/26 8,720.00 +5.06% 176,024
15/04/26 8,300.00 +0.24% 99,171
14/04/26 8,280.00 +0.85% 66,395
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. A137310 Stock